Lung cancer is the leading cause of cancer death worldwide and even today only 10% of people survive lung cancer for 10 years or more in the UK. One challenge in treating lung cancer is that lung ...
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
The review emphasizes how breakthroughs in understanding the molecular mechanisms of cell cycle regulation have paved the way for the development of targeted anti-cancer agents. Notably, inhibitors of ...
New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint ...
Explore new findings on drug-resistant breast cancer and how targeting cell cycle regulators may improve treatment outcomes.
HOUSTON, JANUARY 22, 2026 ― A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center , published today in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results